CYP2C19 and ABCB1 gene polymorphisms are differently distributed according to ethnicity in the Brazilian general population by Santos, Paulo CJL et al.
RESEARCH ARTICLE Open Access
CYP2C19 and ABCB1 gene polymorphisms are
differently distributed according to ethnicity in
the Brazilian general population
Paulo CJL Santos
1, Renata AG Soares
1, Diogo BG Santos
1, Raimundo M Nascimento
2, George LLM Coelho
2,
José C Nicolau
3, José G Mill
4, José E Krieger
1, Alexandre C Pereira
1*
Abstract
Background: Recent studies have reported the clinical importance of CYP2C19 and ABCB1 polymorphisms in an
individualized approach to clopidogrel treatment. The aims of this study were to evaluate the frequencies of
CYP2C19 and ABCB1 polymorphisms and to identify the clopidogrel-predicted metabolic phenotypes according to
ethnic groups in a sample of individuals representative of a highly admixtured population.
Methods: One hundred and eighty-three Amerindians and 1,029 subjects of the general population of 4 regions of
the country were included. Genotypes for the ABCB1c.C3435T (rs1045642), CYP2C19*2 (rs4244285), CYP2C19*3
(rs4986893), CYP2C19*4 (rs28399504), CYP2C19*5 (rs56337013), and CYP2C19*17 (rs12248560) polymorphisms were
detected by polymerase chain reaction followed by high resolution melting analysis. The CYP2C19*3, CYP2C19*4
and CYP2C19*5 variants were genotyped in a subsample of subjects (300 samples randomly selected).
Results: The CYP2C19*3 and CYP2C19*5 variant alleles were not detected and the CYP2C19*4 variant allele
presented a frequency of 0.3%. The allelic frequencies for the ABCB1c.C3435T, CYP2C19*2 and CYP2C19*17
polymorphisms were differently distributed according to ethnicity: Amerindian (51.4%, 10.4%, 15.8%); Caucasian
descent (43.2%, 16.9%, 18.0%); Mulatto (35.9%, 16.5%, 21.3%); and African descent (32.8%, 20.2%, 26.3%) individuals,
respectively. As a result, self-referred ethnicity was able to predict significantly different clopidogrel-predicted
metabolic phenotypes prevalence even for a highly admixtured population.
Conclusion: Our findings indicate the existence of inter-ethnic differences in the ABCB1 and CYP2C19 variant allele
frequencies in the Brazilian general population plus Amerindians. This information could help in stratifying
individuals from this population regarding clopidogrel-predicted metabolic phenotypes and design more cost-
effective programs towards individualization of clopidogrel therapy.
Background
Clopidogrel, a prodrug, is a thienopyridine that inhibits
adenosine diphosphate-induced (ADP) platelet aggrega-
tion. It has been prescribed mainly in patients with acute
coronary syndromes (with or without ST-segment eleva-
tion) and patients submitted to percutaneous coronary
intervention. It is a pro-drug that requires hepatic metabo-
lization and activation by the cytochrome P450 (CYP) in
order to produce its active metabolite. Metabolization of
the drug is achieved by a number of different CYP isoen-
zymes. Two oxidative steps are essential, which culminates
in the active metabolite. In particular, the isoenzyme
CYP2C19 is involved in the two steps contributing to an
estimated 45% of first step and 21% of its change to the
active metabolite [1-3].
Several studies have demonstrated an association
between CYP2C19 gene polymorphisms and the enzyme
activity [4-9]. The most common genetic variation, desig-
nated CYP2C19*2 (c.G681A), leads to a splicing defect
that functionally affects the enzyme. Other alterations
have also been reported as loss-of-function: CYP2C19*3
(c.G636A; stop codon), CYP2C19*4 (c.A1G; transition in
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acid substitution) [7-9].
CYP2C19*2 allelic variant has been associated with
higher levels of ADP-induced platelet aggregation values
in clopidogrel-treated patients and, consequently, a
higher risk of adverse cardiovascular events, such as the
occurrence of stent thrombosis [4-8]. In contrast, an
allelic variant recently reported, CYP2C19*17 (c.C806T;
5’-flanking region of the gene), has been associated with
increased enzyme function [10]. Thus, individuals har-
boring this genetic variant could have an enhanced
response to antiplatelet treatment with clopidogrel,
improving the prevention of thrombotic events, but, on
the other hand, having a putative increased risk of
bleeding [7,10].
On the other hand, it is known that the bioavailability
of clopidogrel and of other drugs is also limited by
absorption. The multidrug resistance gene (MDR1 or
ABCB1) encodes a drug-efflux transporter called P-gly-
coprotein, which functions as a physiologic intestinal
barrier against drug absorption [11]. Some studies evalu-
ating patients receiving clopidogrel have reported that
the rate of cardiovascular events and the plasma concen-
trations of clopidogrel activem e t a b o l i t ew e r ed i f f e r e n t
according to the genotype for the polymorphism c.
C3435T in the ABCB1 gene [8,11].
In addition, it has been observed that the genotypic
frequencies of CYP2C19 and ABCB1 polymorphisms
present some degree of variation among different ethnic
groups [12,13]. As a result, the prevalence of the pre-
dicted metabolic phenotypes associated with these poly-
morphisms may vary significantly among different
world-wide populations, leading the impact of pharma-
cogenetic testing for these variants extremely dependent
on a particular country/population genetic architecture.
The Brazilian population is one of the most heteroge-
neous in the world, being a mixture of different ethnic
groups, composed mainly of European descent, African
descent and Amerindians [14]. The main aims of this
s t u d yw e r et oe v a l u a t et h ef r e q u e n c i e so fCYP2C19 and
ABCB1 polymorphisms and to identify the clopidogrel-




This study included 1,029 subjects of the general popu-
lation selected using the Hearts of Brazil Project (HBP)
[15]. The universe of the HBP consisted in the set of
inhabitants of Brazilian urban centers with more than
100,000 inhabitants. The HBP sample plan was calcu-
lated as 2,500 interviews, distributed in the 5 regions of
the country proportionally to the number of inhabitants,
per sex and age range, based on data from IBGE
(Brazilian Institute of Geography and Statistic). A total
of 72 cities were chosen in the five regions. The mini-
mum sample size was set at 15, for smaller towns, up to
400, for the city of Sao Paulo (Additional file 1, Figure
S1). In the selected cities, the “households” constituted
the second-stage units, with one interview per house-
hold. Subjects were separated in self-identified sub-
groups according to ethnicity, as Caucasian descent,
African descent, or Mulattos (considered racially mixed
subjects) [15].
In addition, one hundred and eighty-three Amerin-
dians derived from two different groups (Guarani and
Tupinikin; Aracruz Indian Reserve, Espirito Santo State
in the Southeast Brazilian coast) were also analyzed.
The study protocol was approved by the involved Insti-
tutional Ethics Committees and National Ethic Commit-
tee for Human Research (CONEP Register Number
4599), and written informed consent was obtained from
all participants prior to entering the study.
Genotyping
Genomic DNA was extracted from peripheral blood leu-
kocytes following a standard salting-out method [16].
Genotypes for the ABCB1c.C3435T (rs1045642),
CYP2C19*2 (c.G681A; rs4244285), CYP2C19*3 (c.
G636A; rs4986893), CYP2C19*4 (c.A1G; rs28399504),
CYP2C19*5 (c.C1297T; rs56337013), and CYP2C19*17
(c.C806T; rs12248560) polymorphisms were detected by
polymerase chain reaction (PCR) followed by high reso-
lution melting analysis [17,18] (HRM; Rotor Gene
6000
®, Qiagen, Courtaboeuf, France) using the primer
sequences listed in Table 1.
The PCR was performed with addition of fluorescent
DNA-intercalating SYTO9
® (Invitrogen, Carlsbad, USA).
In the HRM phase, the Rotor Gene 6000
® measured the
fluorescence in each 0.1°C temperature increase in the
range of 70-94°C. Melting curve was generated by the
decrease in fluorescence with the increase in the tem-
perature; and in analysis, nucleotide changes results in
different curve patterns. Samples of the three observed
curves were sequenced (ABI Terminator Sequencing
Kit
® and ABI 377 Sequencer
® - Applied Biosystems,
F o s t e rC i t y ,C A ,U S A )t oc o n f i r mt h eg e n o t y p e si n d i -
cated by HRM.
Predicted metabolic phenotypes
Regarding the predicted metabolic phenotypes related
to CYP2C19 polymorphisms, individuals were grouped
into distinct phenotypes: extensive metabolizer (EM:
wild-type for the CYP2C19 polymorphisms), intermedi-
ate metabolizer (IM: heterozygous genotype for the
loss-of-function CYP2C19 polymorphisms and wild-
type for the CYP2C19*17), poor metabolizer (PM:
homozygous or compound heterozygous genotypes for
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ultra-rapid metabolizer (UM: heterozygous or homozy-
gous genotypes for the CYP2C19*17 and wild-type for
the CYP2C19*2). The predicted metabolic phenotype
of individual carrying homozygous or heterozygous
genotypes for the CYP2C19*17 polymorphism plus het-
erozygous genotype for the CYP2C19*2 polymorphism
are unknown. The individuals carrying homozygous
genotype for the *2 (*2/*2) plus heterozygous or homo-
zygous genotype for the *17 were classified as PM,
because the first alteration leads to a loss-function
enzyme, while a second causes an increased transcrip-
tion (Additional file 1, Table S1) [6,7].
Statistical Analysis
Chi-square test was performed for comparative analysis
of the allelic and genotypic frequencies for the ABCB1
and CYP2C19 polymorphisms and of the predicted meta-
bolic phenotype frequency according to ethnicity (Amer-
indian, Caucasian descent, Mulatto, African descent).
Chi-square test was also performed for the determination
of differences of allelic frequency for the ABCB1 and
CYP2C19 polymorphisms, of ethnicity according to Bra-
zilian regions, and for the comparative analysis between
our data and previous reports. Hardy-Weinberg equili-
brium and linkage disequilibrium analyses were con-
ducted with Haploview 4.0. All other statistical analyses
were carried out using the SPSS software (v. 16.0), with
the level of significance set at p < 0.05.
Results
General data of the studied sample
Of the 1,212 subjects (mean age 43.2 ± 14.2), 651
(53.7%) were female and 561 (46.3%) male. Ethnic group
distribution was: Amerindians 15.1% (n = 183), Cauca-
sian descent 50.7% (n = 615), Mulatto 26.0% (n = 315)
and African descent 8.2% (n = 99).
Of the 1,029 subjects from the general population, 615
(59.8%) individuals belonged to the Southeast region,
198 (19.2%) to the Northeast region, 114 (11.1%) to the
South region, 98 (9.5%) to the Midwest region, and only
4 (0.4%) to the North region of the country. The South
region presented the highest frequency of Caucasian
descent subjects (86.0%) as opposed to the Northeast
region (52.0%), while the Northeast and Midwest regions
presented higher frequencies of African descent subjects
(11.1% and 9.2%) as opposed to the South region (4.4%)
(p < 0.001). These results are in accordance to the
described by the IBGE (Brazilian Institute of Geography
and Statistic) on the last Brazilian census report.
Frequencies of the ABCB1 c.C3435T polymorphism
The frequencies of the variant allele (51.4%) and of the
homozygous genotype (27.3%) for the ABCB1c.C3435T
polymorphism were higher in Amerindians compared
with Caucasian descent (43.2%; 19.8%), Mulatto (35.9%;
13.3%), and African descent (32.8%; 13.1%), respectively
(p < 0.001) (Table 2).
Frequencies of the CYP2C19 polymorphisms
The frequencies of the CYP2C19*2 variant allele and of
the homozygous genotype were higher in African descent
individuals (20.2% and 6.0%) and were lower in Amerin-
dians (10.4% and 3.8%) compared with other ethnic
groups (p = 0.013 and p = 0.007, respectively) (Table 2).
The CYP2C19*3 and CYP2C19*5 variant alleles were
not detected in a subsample of subjects from this study
(300 samples randomly selected). However, the
CYP2C19*4 variant allele was observed in two samples
in the heterozygous form (allelic frequency of 0.3%).
The frequency of the CYP2C19*17 variant allele was
higher in African descent subjects (26.3%) and was
lower in Amerindians (15.8%) compared with other eth-
nic groups (p = 0.048) (Table 2).
Table 1 Primers used for amplification of the ABCB1 and CYP2C19 polymorphisms
Name Primer sequence Fragment size (bp) Anelling temperature (°C)
ABCB1c.C3435T F 5’ GGGTGGTGTCACAGGAAGAG3’ 74 59.6
ABCB1c.C3435T R 5’ CCTTCATCGAGTCACTGCCT 3’
CYP2C19*2 F 5’ TGCAATAATTTTCCCACTATCA 3’ 83 50.5
CYP2C19*2 R 5’ CCTTGCTTTTATGGAAAGTGA 3’
CYP2C19*3 F 5’ CCTTGCTTTTATGGAAAGTGA 3’ 75 50.5
CYP2C19*3 R 5’ TTTTTGCTTCCTGAGAAACCA 3’
CYP2C19*4 F 5’ GCAAGCTCACGGTTGTCTTA 3’ 70 63.4
CYP2C19*4 R 5’ TGTGGTCCTTGTGCTCTGTC 3’
CYP2C19*5 F 5’ TGGAAGTTGTTTTGTTTTGCT 3’ 110 59.6
CYP2C19*5 R 5’ TAAGAGATAATGCGCCACGA 3’
CYP2C19*17 F 5’ AAATTTGTGTCTTCTGTTCTCAAA 3’ 100 56.7
CYP2C19*17 R 5’ AATCCCAGTTCTGCCAGCTA 3’
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CYP2C19*17 variant alleles according to ethnic groups
Linkage disequilibrium analysis show that the CYP2C19*2
and CYP2C19*17 variant alleles are in different linkage
disequilibrium patterns depending on ethnic origin
(Amerindian: 12; Caucasian descent: 54; Mulatto: 53;
African descent: 1).
Frequencies of the ABCB1 and CYP2C19 variant alleles
according to Brazilian regions
Higher ABCB1c.C3435T variant allele frequency was
observed in the South region (44.0%), while a lower preva-
lence was presented in the Midwest region (32.0%) (p =
0.017). The Midwest region presented higher frequency of
subjects carrying CYP2C19*2 variant allele (26.0%) com-
pared with other regions (p = 0.003). For the CYP2C19*17
variant allele no difference in the frequency between
regions was observed (Additional file 1, Figure S2).
Frequencies of the predicted metabolic phenotypes
according to ethnic groups
The proportion of EM individuals was significantly
higher in Amerindians (62.3%) than in Caucasian des-
cent (47.0%), Mulatto (40.6%) and African descent
(33.3%) (p < 0.001). The frequency of IM individuals
was higher in African descent subjects (19.2%) than in
other groups (p = 0.010). African descent subjects
(32.3%) presented a higher frequency of the UM pre-
dicted phenotype, while the Amerindians presented
lower frequency (20.8%) (p = 0.048). However, no differ-
ences were observed in the frequency of PM individuals
according to ethnicity (Table 3) (p = 0.549) (Additional
file 1, Table S1 and Table S2).
The predicted metabolic phenotype of individual car-
rying homozygous or heterozygous genotypes for the
CYP2C19*17 polymorphism plus a heterozygous geno-
type for the CYP2C19*2 polymorphism (*2/*17) are
unknown. The frequencies of these genotype combina-
tions were similar in Amerindians (4.4%), Caucasian
descent (5.5%), Mulatto (6.0%), and African descent
(9.1%) groups (p = 0.429) (Table 3).
Discussion
Probably the main contribution of the present study was
the demonstration, in the Brazilian population of signifi-
cant differences between the allelic and genotypic fre-
quencies of polymorphisms associated to clopidogrel,
according to ethnicity. To our knowledge this is the first
study evaluating CYP2C19 polymorphisms in Brazilian
Amerindians plus a sample representative of the Brazilian
general population. These results could be very useful in
the strategic planning of the implementation of pharma-
cogenetic testing for these variants, aiming at an indivi-
dual therapeutic approach and adverse drug effect profile
prediction both, at the individual and regional country
level. To our knowledge, there is no implemented
genetic-based prescription program in Brazil; however,
the study by Gladding et al concluded that genotyping
for the relevant gene polymorphisms may help to indivi-
dualize and optimize clopidogrel treatment [19].
One potential limitation relates to the self-referred
ethnicity. However, this type of classification is the one
most probable to be encountered in real-life situations.
In addition, even self-referred ethnicity was able to
clearly differentiate groups of individuals with rather dif-
ferent allele and genotype frequencies. Finally, different
Table 2 Allelic and genotypic frequencies of ABCB1 and CYP2C19 gene polymorphisms according to ethnic groups












CC 45 (24.6%) 206 (33.5%) 131 (41.6%) 47 (47.5%)
CT 88 (48.1%) 287 (46.7%) 142 (45.1%) 39 (39.4%) <0.001
TT 50 (27.3%) 122 (19.8%) 42 (13.3%) 13 (13.1%)
T allele 51.4% 43.2% 35.9% 32.8% <0.001
CYP2C19*2, c.G681A
GG 151 (83.1%) 439 (71.4%) 222 (70.5%) 65 (65.7%)
GA 24 (13.1%) 144 (23.4%) 82 (26.0%) 28 (28.3%) 0.013
AA 7 (3.8%) 32 (5.2%) 11 (3.5%) 6 (6.0%)
A allele 10.4% 16.9% 16.5% 20.2% 0.007
CYP2C19*17, c.C806T
CC 134 (73.2%) 425 (69.1%) 201 (63.8%) 55 (55.6%)
CT 40 (21.9%) 158 (25.7%) 94 (29.8%) 36 (36.4%) 0.065
TT 9 (4.9%) 32 (5.2%) 20 (6.4%) 8 (8.0%)
T allele 15.8% 18.0% 21.3% 26.3% 0.048
ABCB1c.C3435T (rs1045642); CYP2C19*2 c.G681A (rs4244285); CYP2C19*17 c.C806T (rs12248560).pvalues were calculated using Chi-square test.
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individuals were separated by the country’s geographic
region. Although a great amount of this effect was prob-
ably due to different ethnic distribution according to
regions, both variables were independently predictive of
genotype distribution in multivariate models adjusted by
both ethnic group and country region (data not shown).
Probably interaction effects, as well as other confoun-
ders, could explain these findings. In fact, one should
not dissociate ethnic group self-referral from country
region, since cultural aspects may modulate the way
people describe themselves regarding ethnicity and this
certainly may differ in different parts of the country.
This effect should be studied in future works.
Similarly, interethnic differences were observed in the
VKORC1 polymorphism in 4,886 individuals of 11 coun-
tries (Asians, African descent and Caucasian descent),
and the contribution of VKORC1 toward dose require-
m e n t si sh i g h e ri nw h i t e st h a ni nn o n w h i t e s[ 2 0 ] .O t h e r
study reported the worldwide allele frequency distribu-
tion of four genetic polymorphisms known to influence
warfarin dosing and concluded that understanding the
worldwide distribution of markers is important for the
future application of pharmacogenomic-based algo-
rithms to different population groups [21].
The ABCB1 gene encodes a P-glycoprotein that
exports drugs, including clopidogrel. Simon et al (2009)
studied 2,208 patients presenting with an acute myocar-
dial infarction and receiving clopidogrel therapy. They
reported that patients carrying one or two variant alleles
for the ABCB1 c.C3435T polymorphism presented more
than five times the rate of adverse events of patients
with the wild-type genotype [8].
The ABCB1 c.C3435T variant allele frequencies
reported in studies using samples from African indivi-
duals (Ghanian and Kenyan [22]) was of 17.0%. We
observed in African descent subjects a higher frequency
(32.8%) than in the two cited studies, but this frequency
was lower than in other ethnic groups of our study (p <
0.001). In studies of Caucasians subjects (French, 43.0%
[23]; Spanish, 48.0% [24]; German, 48.0% [25]; Polish,
49.0% [26]), the variant allele frequency was similar (p >
0.050) to the observed in our sample of Caucasian
descent (43.2%) and Amerindian (51.4%) individuals.
This result is probably explained by undetected (or
unreferred) admixture history of the studied individuals
self-referred as African descent from the Brazilian
population.
The absence of CYP2C19*3 and CYP2C19*5 variant
alleles and the rare frequency of CYP2C19*4 variant
allele (0.3%) in our study does not exclude the existence
of individuals with PM or IM predicted metabolic phe-
notypes by presence of these loss-of-function alleles in
the Brazilian population. Nevertheless, it clearly shows
that these variants are less powerful for the cost-effec-
tiveness design of programs aiming at the identification
of individuals harboring predicted metabolic phenotypes
compared to the CYP2C19*2 and *17 alleles.
The CYP2C19*2 variant allele frequency found in our
study was higher (p < 0.05) in African descent subjects
(20.2%) compared with other ethnic groups and with
Italian [27] (11.1%); European American [13] (13.0%);
and German [28] (15.9%) subjects. However, this fre-
quency was similar (p > 0.05) to the observed in samples
of other African descent populations: African American
[13] (25.0%), and African Venda [29] (22.0%).
In the general population, the PM predicted metabolic
phenotype frequency (4.8%; 49/1029) was lower (p <
0.050) than in Japanese [30] (15.0%). In contrast, it was
higher (p < 0.05) than in European American [13]
(2.0%) and in Italians [27] (1.7%).
The phenotypic implications of the CYP2C19*2 poly-
morphism have been established in recent studies using
clopidogrel. Mega et al (2009) observed that carriers of
a reduced-function CYP2C19*2 allele have significantly
lower levels of the active metabolite of clopidogrel,
diminished platelet inhibition, and a higher rate of
major adverse cardiovascular events, including stent
thrombosis [6]. Simon et al (2009) reported that this
genetic variant was associated with an increase in the
risk of death, myocardial infarction, or stroke, especially
among patients undergoing percutaneous coronary
intervention [8].
The CYP2C19*17 variant allele, and the UM predicted
phenotype, prevalence found was higher in African des-
cent subjects (26.3%; 32.3%) and lower in Amerindians
Table 3 Distribution of predicted metabolic phenotypes and observed genotypes according to ethnic groups
Gene
n (100%)









UM *17/*17, *1/*17 38 (20.8%) 150 (24.4%) 94 (29.8%) 32 (32.3%) 0.048
EM *1/*1 114 (62.3%) 289 (47.0%) 128 (40.6%) 33 (33.3%) <0.001
CYP2C19 IM *1/*2 16 (8.8%) 110 (17.9%) 63 (20.1%) 19 (19.2%) 0.010
PM *2/*2 7 (3.7%) 32 (5.2%) 11 (3.5%) 6 (6.1%) 0.549
Unknown
a *2/*17 8 (4.4%) 34 (5.5%) 19 (6.0%) 9 (9.1%) 0.429
CYP2C19*2 c.G681A (rs4244285); CYP2C19*17 c.C806T (rs12248560). UM: ultra-rapid metabolizer; EM: extensive metabolizer; IM: intermediate metabolizer; PM: poor
metabolizer.
a The predicted metabolic phenotypes of the *2/*17 genotypic combination is unknown. p values were calculated using Chi-square test.
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0.048). Some studies have reported lower frequencies of
this variant allele in Chinese (4.0%) [10], Japanese (1.3%)
[31] and Korean (0.3%) [32]; and similar frequencies
in Swedish (20.0%) [32]; and Greek (19.6%) [33].
CYP2C19*17 is a recently reported variant causing ultra-
rapid metabolism of CYP2C19 substrates. Regarding clo-
pidogrel, Sibbing et al. (2010) observed that patients car-
rying heterozygous or homozygous genotypes (UM
predicted phenotype) had lower ADP-induced platelet
aggregation values compared with wild-type. In addition,
CYP2C19*17 allele carriage was significantly associated
with an increased risk of bleeding [7].
It is interesting that the genetic and functional knowl-
edge of a CYP2C19 enzyme provide enough information
to identify patients who will fall outside the therapeutic
window of clopidogrel. Thus, it would be possible to
justify increases in dosage or a change in therapy. How-
ever, it is important to consider that this metabolism
has many influences (other genetic markers, concomi-
tant disease processes, medications, foods, age and life-
style), all of which culminate in variations in the drug
action and in the effectiveness of the therapeutic regi-
men [9,34].
Conclusion
Our findings indicate the existence of interethnic differ-
ences in the ABCB1 and CYP2C19 variant allele and
predicted metabolic phenotype frequencies in the Brazi-
lian general population plus Amerindians. Recent stu-
dies, have reported the clinical importance of these
polymorphisms. The results of the present study will be
very useful in the development of effective programs in
stratifying individuals regarding clopidogrel-predicted
metabolic phenotypes.
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